ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Defence Therapeutics Inc (QB)

Defence Therapeutics Inc (QB) (DTCFF)

0.40472
-0.00923
(-2.23%)
Closed November 08 4:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.40472
Bid
0.20
Ask
0.7468
Volume
800
0.40472 Day's Range 0.40472
0.40 52 Week Range 2.18
Market Cap
Previous Close
0.41395
Open
0.40472
Last Trade
300
@
0.40472
Last Trade Time
Financial Volume
$ 324
VWAP
0.40472
Average Volume (3m)
1,125
Shares Outstanding
45,536,673
Dividend Yield
-
PE Ratio
-1.38
Earnings Per Share (EPS)
-0.29
Revenue
-
Net Profit
-13.19M

About Defence Therapeutics Inc (QB)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Vancouver, British Columbia, Can
Founded
-
Defence Therapeutics Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker DTCFF. The last closing price for Defence Therapeutics (QB) was $0.41. Over the last year, Defence Therapeutics (QB) shares have traded in a share price range of $ 0.40 to $ 2.18.

Defence Therapeutics (QB) currently has 45,536,673 shares outstanding. The market capitalization of Defence Therapeutics (QB) is $18.85 million. Defence Therapeutics (QB) has a price to earnings ratio (PE ratio) of -1.38.

DTCFF Latest News

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

 DEFENCE RETAINS CATO SMS TO ADVISE ON ITS  PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER  Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

  Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9   Vancouver, BC, Canada, January 26th...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER   Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

 DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

  VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS   Vancouver, BC, Canada, November...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

  DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER   Vancouver, BC, Canada, October 13th...

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

    DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

 DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...

DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS

 DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS Vancouver, BC, Canada, September 20th, 2021 -- InvestorsHub NewsWire -- Defence...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000.40472000CS
4-0.00502-1.225167179190.409740.43610.404727770.42327575CS
12-0.03338-7.619265007990.43810.5189750.411250.44579826CS
26-0.57318-58.61335514880.97790.97790.410410.61115872CS
52-1.77528-81.43486238532.182.180.412231.36784794CS
156-4.72724-92.11373432375.131965.410.410982.23395937CS
260-2.09528-83.81122.56.40780.411982.84255072CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OBCNObocon Inc (CE)
$ 0.0002
(19,900.00%)
100
NNFCNanoforce Inc (CE)
$ 0.0002
(19,900.00%)
100
AURIAuri Inc New (PK)
$ 0.00015
(14,900.00%)
90.99M
CEVECeres Ventures Inc (CE)
$ 0.0001
(9,900.00%)
207
TWOHTwo Hands Corporation (PK)
$ 0.0001
(9,900.00%)
7.62M
SONXDSonendo Inc
 2.00
(-99.80%)
2.43k
IGOTFOMO Worldwide Inc (CE)
$ 0.000001
(-99.50%)
13.49k
HLLPFHello Pal International Inc (CE)
$ 0.000001
(-99.50%)
48.38k
REFGMedical Cannabis Payment Solutions (CE)
$ 0.000001
(-99.00%)
2.8k
BLSPBlue Sphere Corporation (CE)
$ 0.000001
(-99.00%)
601.99k
CGACCode Green Apparel Corp (PK)
$ 0.0005
(400.00%)
773.64M
HMBLHUMBL Inc (PK)
$ 0.0003
(0.00%)
228.82M
NSAVNet Savings Link Inc (PK)
$ 0.0015
(172.73%)
224.69M
VIZCVizConnect Inc (PK)
$ 0.0004
(14.29%)
194.29M
PSWWPrincipal Solar Inc (PK)
$ 0.0003
(20.00%)
189.83M

Your Recent History

Delayed Upgrade Clock